Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease
Purpose: Complement C1q, the initiating molecule of the classical complement cascade, is involved in synapse elimination and neuronal loss in neurodegenerative diseases including glaucoma. Here we report an evaluation of the safety, tolerability, and ocular pharmacokinetics (PK) and pharmacodynamics...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-06-01
|
Series: | Ophthalmology Science |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666914523000222 |